Breakdown | |||||
TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
673.82B | 648.13B | 611.29B | 572.75B | 559.15B | 523.96B | Gross Profit |
166.41B | 157.98B | 147.57B | 143.75B | 138.84B | 129.36B | EBIT |
28.74B | 27.01B | 20.43B | 25.94B | 22.55B | 20.57B | EBITDA |
38.20B | 38.87B | 30.09B | 36.60B | 34.03B | 33.70B | Net Income Common Stockholders |
19.68B | 15.51B | 11.68B | 13.67B | 13.51B | 14.88B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
9.87B | 9.87B | 8.88B | 14.76B | 17.74B | 9.46B | Total Assets |
252.40B | 252.40B | 243.46B | 244.86B | 252.50B | 236.50B | Total Debt |
61.32B | 61.32B | 58.92B | 57.32B | 63.25B | 72.43B | Net Debt |
51.45B | 51.45B | 50.04B | 42.56B | 45.51B | 62.97B | Total Liabilities |
161.83B | 161.83B | 159.47B | 152.97B | 164.97B | 154.94B | Stockholders Equity |
83.86B | 83.86B | 76.69B | 83.25B | 81.30B | 74.67B |
Cash Flow | Free Cash Flow | ||||
17.00B | 15.12B | 11.98B | 11.07B | 25.81B | 14.55B | Operating Cash Flow |
39.63B | 35.73B | 28.84B | 24.18B | 36.07B | 25.25B | Investing Cash Flow |
-18.57B | -21.29B | -17.72B | -6.01B | -10.07B | -9.13B | Financing Cash Flow |
-22.91B | -13.41B | -16.21B | -22.83B | -16.12B | -14.30B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
82 Outperform | $2.16T | 36.91 | 20.72% | ― | 10.99% | 91.61% | |
78 Outperform | $460.27B | 60.89 | 30.98% | 0.44% | 5.35% | 16.22% | |
77 Outperform | $762.93B | 39.41 | 22.33% | 0.85% | 5.07% | 25.86% | |
73 Outperform | $13.35B | 24.28 | 31.64% | ― | 5.32% | 10.61% | |
70 Outperform | $53.67B | 12.41 | 30.16% | 3.69% | 0.64% | 20.16% | |
68 Neutral | $45.51B | 16.64 | 21.45% | 1.99% | 1.41% | 46.58% | |
63 Neutral | $20.85B | 13.27 | -10.88% | 7.48% | 1.13% | 11.50% |
Walmart Inc. announced a settlement agreement to resolve shareholder derivative actions relating to allegations that certain directors and officers failed to oversee the company’s opioid distribution. If approved by the Delaware Court, the settlement will include a $123 million payment from insurance carriers and the adoption of corporate governance practices for five years. This move aims to address investor concerns without admitting liability, offering a resolution to ongoing legal disputes.